Gastric Cancer
Conditions
Keywords
Gastric cancer, Camrelizumab, neoadjuvant, chemotherapy
Brief summary
For locally advanced gastric cance, neoadjuvant chemotherapy can increase the resectability of tumor, and finally improve the long-term survival. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced gastric cancer could be a novel therapy to increase response rate and resectability and reduce recurrence rate. Camrelizumab（SHR-1210） in this study is a Chinese anti-PD-1 monoclonal antibody for injection which has been approved for melanoma and Hepatocellular carcinoma. This study is a single center, open-label, randomized comparative phase II clinical trial to evaluate safety and efficacy of Camrelizumab in combination with perioperative chemotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Differences in T cell expression were detected by single cell RNA sequencing to screen people who were more sensitive to immunotherapy.
Detailed description
Gastric cancer is one of the most common malignancies in China with incidence and mortality both ranking the 2nd among malignancies in China. Surgery is the only possible way to cure gastric cancer, however, over 80-90% of gastric cancer patients in China are in advanced stage. Locally advanced gastric cancer could be cured by multi-disciplinary therapies including surgery, chemotherapy and radiotherapy. Neoadjuvant chemotherapy can increase the resectability of tumor, and finally improve the long-term survival. However, the therapeutic effects remain unsatisfactory. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced gastric cancer could be a novel therapy to increase response rate and resectability and reduce recurrence rate. Camrelizumab in this study is a Chinese anti-PD-1 monoclonal antibody for injection which has been approved for melanoma and Hepatocellular carcinoma .This study is a single center, open-label, randomized comparative phase II clinical trial to evaluate safety and efficacy of Camrelizumab in combination with perioperative chemotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Differences in T cell expression were detected by single cell RNA sequencing to screen people who were more sensitive to immunotherapy.
Interventions
DRUGCamrelizumab
Camrelizumab: 200mg,iv drip for 1h,d1,q3w
DRUGOxaliplatin
Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
DRUGS1
S-1:40\ 60mg Bid, d1\ 14, q3w;
Sponsors
Chinese PLA General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Written (signed) informed consent. 2. Age ≥ 18 years and ≤70 years. 3. ECOG Performance status 0-1. 4. Has previously untreated localized gastric or gastroesophageal junction adenocarcinoma as defined by T3 or greater primary lesion or the presence of any positive nodes - N+ (clinical nodes) without evidence of metastatic disease. 5. Patients who plan surgery after neoadjuvant chemotherapy based on clinical staging criteria. 6. Consent to send tumor tissue from biopsy or resection for PD-L1 detection and PD-L1 CPS≥1; 7. Expected survival ≥6 months; 8. Females of child bearing age must have a negative pregnancy test 9. 1）Platelet (PLT) ≥100×109/L; 2) Neutrophil count (ANC)≥1.5×l09/L; 3) Hemoglobin (Hb) level ≥9.0 g/dl; 4）WBC≥3.5×l09/L; 5) International normalized ratio (INR) ≤1.5; 5) Prothrombin time (PT) ,International Normalized Ratio（INR）and activated partial thromboplastin time (APTT) ≤1.5×ULN; 6）Total bilirubin (TBIL) level ≤1.5×ULN（patients with gilbert syndrome≤3×ULN）; 7) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level ≤2.5×ULN ; 10) Serum creatinine (Cr) level ≤1.5×ULN and creatinine clearance ≥60 ml/min;
Exclusion criteria
1. Patients with pathologically confirmed gastric squamous cell carcinoma, adenosquamous carcinoma, small cell carcinoma, and undifferentiated gastric cancer. 2. patients who have HER2 positive confiemed with IHC3+ or IHC2+ and FISH positive. 3. Patients with a history of t Anticancer or Experimental Therapy(Including chemotherapy, radiotherapy, hormone therapy and molecular targeted therapy) 4. The patient's cardia or pylorus is nearly obstructed, affecting eating and gastric emptying 5. Immunotherapy with previous anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibodies or any other antibody or drug that targets T-cell co-stimulation or immune checkpoint pathways 6. Patients have experienced or currently has other malignancies within 5 years.Except for the cured cervical carcinoma in situ,Non-melanoma skin cancer, Other tumors or cancers that have been treated radically and have shown no signs of disease for at least 5 years. 7. Peripheral neuropathy ≥ level 2（according to CTCAE 5.0） 8. Patient currently has CNS or cancerous meningitis. 9. Patients are allergic to study medication and its ingredients 10. Patients have hereditary bleeding or coagulopathy at risk of bleeding 11. Patient underwent major surgery within 4 weeks 12. Patients have taken Chinese herbal medicine or proprietary Chinese medicine for cancer treatment within two weeks 13. Patients have not recovered from complications of previous surgery.According to the CTCAE 5.0, it has not been reduced below level 1(In addition to hair loss and fatigue) 14. Patients require immunosuppressive drugs within 2 weeks or less or during the study.Exclude the following: A) Use of intranasal, inhaled or topical steroid(For example, intra - articular injection) B) physiological dose of steroid ( Prednisone less than 10mg per day or use equivalent dose) C) Short-term(no more than 7 day) use of steroids to prevent or treat non-autoimmune allergic diseases 15. Patients have an active or history of autoimmune disease that may recur 16. Patients have a history of interstitial lung disease or non-infectious pneumonia 17. Patients have a history of active tuberculosis 18. Patients have a history of HIV infection or other acquired, congenital immunodeficiency disease , organ transplant or stem cell transplant 19. Hepatitis B or C virus virological tests meet any of the following: A) HBsAg positive ,HBV-DNA≥150 copies/mL or ≥2000IU/mL B) HCV antibody positive and HCV-RNA is above the detection limit of the analysis method 20. Within 2 weeks or 2 weeks before randomization,Patients have an active or uncontrollable infection that requires systemic treatment 21. Patient vaccinated with live virus within 4 weeks 22. Patients have uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage or treatment. 23. Patients have gastrointestinal perforation or fistula within 6 months and significant clinically significant gastrointestinal bleeding before 3 months of randomization 24. Patient have intestinal obstruction, inflammatory bowel disease, extensive bowel resection, Crohn's disease, ulcerative colitis or chronic diarrhea 25. Patients have serious internal medicine diseases 26. Women who are pregnant, breast-feeding or planning to become pregnant during treatment or within 6 months after treatment ends. 27. Patients are unwilling to receive effective contraception during treatment and within 6 months after treatment ends 28. The investigator believes that the subject is not suitable for the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major pathologic response (MPR) | At time of surgery | It is defined as residual tumors less than 10% after neoadjuvant chemotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate(ORR) | From the initiation date of first cycle (each cycle is 21 days) to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years | It is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR. |
| pCR | From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 12 weeks | Pathological complete response |
| Disease-free survival (DFS) | 3years | The time from the beginning of randomization to the recurrence of the disease or the death of the patient due to disease progression |
| Overall survival(OS) | From the initiation date of first cycle to the date of first documented progression or date of death from any cause, whichever came first,assessed up to 3 years | The Kaplan-Meier survival from the initiation date of first cycle until death from any cause or the last follow-up date. |
| OSR | 3years | overall survival rate |
Countries
China
Contacts
Primary ContactBaoqing Jia, professor
Outcome results
None listed